- New SMCxPRO™ technology offers high speed, high sensitivity for single molecule detection
- Meets customer demand for biomarker and novel target discovery and detection
BILLERICA, Mass., April 3, 2017 /PRNewswire/ -- MilliporeSigma today announced the launch of its newest high-sensitivity detection platform, SMCxPRO™ technology, at the American Association for Cancer Research Annual Meeting in Washington, D.C.
The SMCxPRO™ platform allows researchers to detect and quantify low-abundance biomarkers that traditional methods cannot measure. The instrument features a high-sensitivity detection system, with speed and accuracy, in a compact design.
It will be available in Q3 of 2017.
"MilliporeSigma's newest innovation, SMCxPRO™ technology, is part of a suite of tools for detecting and characterizing, accelerating drug discovery and improving overall lab productivity," said Jason Apter, Head of Research Solutions Strategic Marketing & Innovation at MilliporeSigma. "Detection of low-abundance biomarkers allows for quantitation of a new class of novel targets. We are committed to empowering researchers by providing the technologies needed to accelerate advancements in healthcare."
Along with the new SMCxPRO™ technology, MilliporeSigma offers a wide range of solutions for biomarker discovery and novel target identification including its recently released Sanger CRISPR libraries that expand the company's suite of gene editing tools.
AACR attendees are encouraged to visit booth #931 to learn more about MilliporeSigma's products and to speak with company experts. Follow us on twitter @MilliporeSigma.
All Merck KGaA, Darmstadt, Germany news releases are distributed by email at the same time they become available on the EMD Group website. In case you are a resident of the U.S. or Canada please go to www.emdgroup.com/subscribe to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials – and generated sales of €12.85 billion in 2015. Around 50,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges.
Merck KGaA, Darmstadt, Germany is the world's oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70 percent interest, the founding family remains the majority owner of the company to this day. The company holds the global rights to the name and the trademark "Merck" internationally except for the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/milliporesigma-introduces-next-generation-high-sensitivity-protein-detection-platform-300433123.html